fullerene c60 has been researched along with 5-carboxytetramethylrhodamine succinimidyl ester in 1 studies
Studies (fullerene c60) | Trials (fullerene c60) | Recent Studies (post-2010) (fullerene c60) | Studies (5-carboxytetramethylrhodamine succinimidyl ester) | Trials (5-carboxytetramethylrhodamine succinimidyl ester) | Recent Studies (post-2010) (5-carboxytetramethylrhodamine succinimidyl ester) |
---|---|---|---|---|---|
3,806 | 5 | 2,170 | 185 | 0 | 112 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Broaddus, WC; Chen, ZJ; Cooper, P; Corwin, F; Dorn, HC; Fatouros, PP; Fillmore, HL; Ge, J; Henderson, SC; Hirsch, JI; Shu, CY; Shultz, MD; Wilson, J; Zhang, J | 1 |
1 other study(ies) available for fullerene c60 and 5-carboxytetramethylrhodamine succinimidyl ester
Article | Year |
---|---|
Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors.
Topics: Amino Acid Sequence; Animals; Brain Neoplasms; Contrast Media; Coordination Complexes; Drug Delivery Systems; Fullerenes; Glioblastoma; Humans; Interleukin-13; Magnetic Resonance Imaging; Mice; Mice, Nude; Molecular Sequence Data; Nanoshells; Peptides; Receptors, Interleukin-13; Rhodamines | 2011 |